Why blood testing is becoming part of oncological medicine

Liquid biopsy has become one of the most discussed areas of modern oncology because it offers a different way of obtaining information about a tumor. In traditional diagnostics, tissue biopsy plays a central role: the physician obtains a fragment of a suspicious lesion, and morphological and molecular examination then helps confirm the diagnosis, determine the tumor type and select treatment. This approach remains the foundation of oncological medicine. However, it has limitations: not every tumor is easy to biopsy, it is not always safe to repeat an invasive procedure, and one tissue sample does not always reflect the full biological heterogeneity of the disease.

The meaning of liquid biopsy is that a tumor can leave molecular traces in biological fluids, especially in blood. Testing may assess fragments of circulating tumor DNA, extracellular RNA, protein markers, DNA methylation, extracellular vesicles or circulating tumor cells. The best-known direction has become the evaluation of circulating tumor DNA. These are small fragments of genetic material that enter the bloodstream when tumor cells die or renew themselves. If such fragments can be detected and interpreted correctly, the physician receives information about the presence of a tumor process, its molecular features or its dynamics after treatment.

Why this matters for early detection. Cancers often become clinically noticeable only when a tumor has reached a significant size or has metastasized. Screening programs do not exist for all tumors, and some oncological diseases remain asymptomatic for a long time. Therefore, the idea of a blood test capable of detecting a tumor signal before a pronounced clinical picture appears is especially attractive. In recent years, multi-cancer early detection tests have been actively developed, aiming to identify signs of several cancer types from a single blood sample. Such tests usually do not search for one universal marker, but use complex panels of molecular features and data analysis algorithms.

The most promising methods are considered to be those that analyze not only mutations, but also epigenetic features. DNA methylation reflects patterns of gene regulation and may differ between tumor and normal cells. This is important for early diagnosis because the amount of circulating tumor DNA at early stages can be very small. The smaller the tumor mass, the weaker the molecular signal in blood. Therefore, test sensitivity depends not only on the quality of the laboratory technology, but also on the biology of the specific tumor, its location, growth rate and ability to release DNA fragments into the bloodstream.

Recent developments show that the field is advancing rapidly, but remains difficult to implement clinically. Regulatory submissions, large screening trials and long-term follow-up studies are gradually clarifying where liquid biopsy can provide real medical value. This creates a dual situation: the technology appears promising, but its actual benefit for population screening must be confirmed in large and prolonged studies. It is not enough for a test to detect more molecular signals; it must also improve clinically meaningful outcomes.

The main clinical requirement for such a test is the balance between sensitivity and specificity. Sensitivity shows how well a test detects disease when it is truly present. Specificity shows how well a test avoids false-positive results in people without disease. For oncological screening, both parameters are critical. If sensitivity is low, some tumors will be missed, creating a false sense of safety. If specificity is insufficient, a large number of people will receive an alarming result followed by additional examinations, imaging, invasive procedures and psychological burden. Therefore, even a small percentage of false-positive results can become a serious problem when a test is applied to millions of people.

Liquid biopsy should not be perceived as an independent diagnosis. A positive blood test result means that further diagnostic verification is needed, but it is not final confirmation of cancer. The physician must compare the result with age, risk factors, symptoms, family history, imaging findings and other test results. It is especially important to determine where the suspected source of the tumor signal is located. Some multi-cancer tests attempt to predict the tissue of origin, but the accuracy of such prediction must also be assessed separately. An error at this stage may lead to unnecessary investigations or delay the correct diagnosis.

Another area of liquid biopsy use is not primary screening, but monitoring of already diagnosed cancer. In many cases, this application is more clinically understandable. After surgery or systemic therapy, analysis of circulating tumor DNA can be used to assess minimal residual disease. If tumor molecular signs remain in the blood after radical treatment, this may indicate an increased risk of recurrence. Such approaches may help determine more precisely who requires more intensive follow-up or additional therapy.

Another important use is the selection of targeted therapy. In advanced cancer, liquid biopsy can identify mutations that help choose a drug or determine a mechanism of drug resistance. For example, if a tumor changes under therapeutic pressure, repeat tissue biopsy may be technically difficult, while a blood test makes it possible to assess new molecular changes less invasively. In this area, liquid biopsy has already gained a more stable position than in mass early screening, because the clinical question is often more specific: whether there is a mutation linked to the choice of a particular treatment.

The future of liquid biopsy will probably not be associated with one universal test, but with different tests for different clinical tasks. One format may be used for risk assessment in selected groups, another for monitoring after treatment, and a third for treatment selection in metastatic disease. An important direction will be the combination of molecular data with artificial intelligence, imaging, clinical factors and traditional laboratory markers. This approach may improve accuracy because cancer rarely manifests through a single signal.

At the same time, caution remains essential. Any new test must prove not only its ability to detect molecular signs of a tumor, but also its real effect on outcomes: reduced mortality, fewer late-stage diagnoses, improved treatment quality or more rational use of medical resources. If a test detects more early signals but does not change the patient’s prognosis, its value is limited. Therefore, liquid biopsy is not a simple replacement for classical diagnostics, but a new diagnostic platform that requires strict clinical validation.

The main significance of liquid biopsy is that it makes oncology more dynamic. A tumor is no longer viewed only as a lesion that can be studied once at the time of diagnosis. Its molecular profile can change, and traces of these changes may appear in blood. For the physician, this opens the possibility of observing disease over time, detecting signs of recurrence earlier, selecting treatment more precisely and better understanding the biology of the tumor process. For the patient, this means a potentially less invasive path of diagnosis and monitoring, but only if every result is interpreted professionally, cautiously and in the context of the full clinical picture.